3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Breast
2
Conditions
Triple Negative Breast Neoplasms
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
HER2-negative Breast Cancer
1
Cardiotoxicity
1
Interventions
pembrolizumab
57
Carboplatin
34
Paclitaxel
24
Cyclophosphamide
23
Capecitabine
18
sacituzumab govitecan
16
Specimen Handling
15
130-nm albumin-bound paclitaxel
15
toripalimab
11
Drug Therapy
11
Biopsy
11
Magnetic Resonance Spectroscopy
10
Bevacizumab
10
Taxes
9
Epirubicin
9
durvalumab
8
Albumin-Bound Paclitaxel
8
olaparib
7
camrelizumab
7
Gemcitabine
7
Doxorubicin
7
Docetaxel
7
fludarabine
6
famitinib
5
Nivolumab
5
Injections
5
atezolizumab
4
abemaciclib
4
Trastuzumab
4
Standard of Care
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Triple Negative Breast Neoplasms
×
Anthracyclines
×
Clear all
NCT06802757
2026-02-25
PRISM-TNBC
Shandong Cancer Hospital and Institute
Phase 2
Recruiting
72 enrolled
NCT05916755
2023-06-23
PORTRAIT
Vall d'Hebron Institute of Oncology
Recruiting
100 enrolled